Sandoz sets out Neulasta biosim plan after Ph III data brings US approval a step closer
Sandoz has confirmed that plants in Europe and Asia will make its version of Neulasta (pegfilgrastim) for the US market if the drug is approved.
Archives for December 8, 2015
Pfizer hails CAB tech in ADC licensing deal with Bioatla
Pfizer and Bioatla have licensed each other’s technology platforms to develop ADCs with Conditionally Active Biologic (CAB) antibodies as the payload delivery vehicles.